Trial · NCT02329080
New Combination of Chemoimmunotherapy for Systemic B-cell Lymphoma With Central Nervous System Involvement
NCT02329080, Phase 2, Completed, International Extranodal Lymphoma Study Group (IELSG); results first posted 2025-07-08
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. New Combination of Chemoimmunotherapy for Systemic B-cell Lymphoma With Central Nervous System Involvement. Trials, record NCT02329080. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02329080
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- New Combination of Chemoimmunotherapy for Systemic B-cell Lymphoma With Central Nervous System Involvement
- NCT number
- NCT02329080
- Status
- Completed
- Phases
- Phase 2
- Enrollment
- 79 participants, actual
- Lead sponsor
- International Extranodal Lymphoma Study Group (IELSG)
- Conditions
- Diffuse Large B-cell Lymphoma
- Interventions
- Methotrexate, Rituximab, Cytarabine, Thiotepa, liposomial cytarabine, Etoposide, Ifosfamide, Carmustine, whole brain radiotherapy
- First posted
- 2014-12-31
- Last updated
- 2025-07-08
- Results first posted
- 2025-07-08
Source ClinicalTrials.gov
Registered outcomes3
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | 1 Year Progression Free Survival (PFS) | From study entry until 1 year after | Percentage of patients free from progression after 1 year from study entry |
| Secondary | 2 Years Progression Free Survival (PFS) | From study entry until 2 years after | Percentage of patients free from progression after 2 years from study entry |
| Secondary | 2 Years Overall Survival (OS) | From trial entry until 2 years after | Percentage of participants alive after 2 years from study entry |
Source ClinicalTrials.gov
Outcomes3
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | 1 Year Progression Free Survival (PFS) | From study entry until 1 year after | Percentage of participants | NUMBER | |
| SECONDARY | 2 Years Progression Free Survival (PFS) | From study entry until 2 years after | percentage of participants | NUMBER | |
| SECONDARY | 2 Years Overall Survival (OS) | From trial entry until 2 years after | percentage of participants | NUMBER |
Source ClinicalTrials.gov
Results by group3
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| 1 Year Progression Free Survival (PFS) | MATRIX - R-ICE - Conditioning and ASCT | 58 | 95% Confidence Interval 55 to 61 | Percentage of participants | |
| 2 Years Progression Free Survival (PFS) | MATRIX - R-ICE - Conditioning and ASCT | 46 | 95% Confidence Interval 39 to 53 | percentage of participants | |
| 2 Years Overall Survival (OS) | MATRIX - R-ICE - Conditioning and ASCT | 46 | 95% Confidence Interval 39 to 53 | percentage of participants |
Source ClinicalTrials.gov
Participant flow3
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | MATRIX - R-ICE - Conditioning and ASCT | 75 | |
| Overall Study | COMPLETED | MATRIX - R-ICE - Conditioning and ASCT | 37 | |
| Overall Study | NOT COMPLETED | MATRIX - R-ICE - Conditioning and ASCT | 38 |
Source ClinicalTrials.gov
Adverse events96
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Vascular Disorders | Vascular disorders | MATRIX - R-ICE - Conditioning and ASCT | 15 | 75 | 23 |
| other | Vascular Disorders | Vascular disorders | Enrolled, But Not Treated | 4 | ||
| other | Cardiac Disorders | Cardiac disorders | MATRIX - R-ICE - Conditioning and ASCT | 8 | 75 | 16 |
| other | Cardiac Disorders | Cardiac disorders | Enrolled, But Not Treated | 4 | ||
| other | Nervous System Disorders | Nervous system disorders | MATRIX - R-ICE - Conditioning and ASCT | 24 | 75 | 67 |
| other | Nervous System Disorders | Nervous system disorders | Enrolled, But Not Treated | 4 | ||
| other | Blood and Lymphatic System Disorders G3-4 | Blood and lymphatic system disorders | MATRIX - R-ICE - Conditioning and ASCT | 51 | 75 | 327 |
| other | Blood and Lymphatic System Disorders G3-4 | Blood and lymphatic system disorders | Enrolled, But Not Treated | 4 | ||
| other | General Disorders and Administration Site Conditions | General disorders | MATRIX - R-ICE - Conditioning and ASCT | 55 | 75 | 121 |
| other | General Disorders and Administration Site Conditions | General disorders | Enrolled, But Not Treated | 4 |
1 to 10 of 96Source ClinicalTrials.gov
See all 96 adverse eventsAdverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | MATRIX - R-ICE - Conditioning and ASCT | 50 | 75 |
| Total, all-cause mortality | Enrolled, But Not Treated | 1 | 4 |
| Total, other adverse events | MATRIX - R-ICE - Conditioning and ASCT | 72 | 75 |
| Total, other adverse events | Enrolled, But Not Treated | 0 | 4 |
| Total, serious adverse events | MATRIX - R-ICE - Conditioning and ASCT | 46 | 75 |
| Total, serious adverse events | Enrolled, But Not Treated | 0 | 4 |
Source ClinicalTrials.gov
Papers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 33513372 | DERIVED |
Source PubMed
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons2
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|---|
| MATRIX - R-ICE - Conditioning and ASCT vs Enrolled, But Not Treated: deaths from any cause | Trial comparisons |
| MATRIX - R-ICE - Conditioning and ASCT vs Enrolled, But Not Treated: serious adverse events | Trial comparisons |
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT02329080
GET https://conductscience.org/api/trials/v1/NCT02329080/events?page=2